What the COSENTYX TV commercial - See Me is about.
COSENTYX is a medication that is used to treat certain types of autoimmune diseases that cause inflammation in different parts of the body. It is specifically used to treat conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis. COSENTYX has recently released a TV spot called "See Me" that features people who are struggling with psoriasis.
In the COSENTYX "See Me" TV spot, a diverse group of individuals is shown to highlight the impact that psoriasis can have on a person's life. The ad begins with close-up shots of people's skin, showing the red, scaly patches that are characteristic of psoriasis. The voiceover then explains that psoriasis can cause patients to feel isolated and misunderstood, and that they may struggle to find a treatment that works for them.
The ad then introduces COSENTYX as a possible solution. The voiceover explains that COSENTYX is a medication that targets the underlying cause of psoriasis, rather than just treating the symptoms. The ad then shows the same individuals from earlier in the spot, but this time their skin is clear and healthy-looking. They smile and discuss how much better they feel now that their psoriasis is under control thanks to COSENTYX.
Overall, the COSENTYX "See Me" TV spot is an emotional and impactful advertisement that aims to connect with people who are struggling with psoriasis. It acknowledges the physical and emotional toll that the condition can have on an individual, and offers hope and a solution in the form of COSENTYX.
COSENTYX TV commercial - See Me produced for
COSENTYX (Psoriasis)
was first shown on television on January 17, 2016.
Frequently Asked Questions about cosentyx tv spot, 'see me'
Cyndi Lauper
In this Cosentyx ad, however, Cyndi Lauper comes across as sincere and believable. She is one of three psoriasis sufferers in the vignette ad and her presence gets attention without being dominant.
Musician Cyndi Lauper was afraid to show her skin and speaks about how painful her psoriasis was. With the help of Cosentyx, she's been clear for over four years and doesn't really think about her skin condition anymore.
Novartis, Cyndi Lauper shine a light on psoriasis challenges in the workplace. Singer-songwriter Cyndi Lauper first joined Novartis' Cosentyx team as a spokesperson more than four years ago, and the two are still churning out initiatives.
COSENTYX TV Spot, 'Enough' Featuring Cyndi Lauper.
Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.
Psoriasis affects many people in the U.S. - and that includes celebrities. Celebrities like Kim Kardashian, Jonathan Van Ness, Art Garfunkel, and Stacy London are some of the celebrities who have spoken out about their condition and how they have learned to manage it.
Bottoms of feet. More than half of people on COSENTYX were clear or almost clear on their scalp as early as 12 weeks compared to 6% taking placebo. Nail psoriasis improved by more than 46% in people receiving COSENTYX compared to an improvement of about 12% in people receiving placebo at week 16.
Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis.
Cyndi Lauper
Her psoriasis didn't appear until she was in her late 50s, but it came on with a vengeance. The award-winning singer and songwriter says it was so bad at times, she couldn't get out of bed. Stress management is a big part of her treatment program, along with an immune-altering drug.
Secukinumab is a drug that reduces the signs and symptoms of psoriatic arthritis, ankylosing spondylitis, and psoriasis. Secukinumab is commonly known as Cosentyx®.
COSENTYX is designed to target and block IL-17A, which is believed to play a role in inflammation that causes psoriasis plaques and joint pain in people with psoriatic arthritis.
Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.